Very difficult when I.O.M. the company will have to double their outstanding shares or do a R/S. I am LONG on the company and can't wait for further approval by FDA and for some analysts to give it a buy rating.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.